Community Research and Development Information Service - CORDIS

Horizon 2020 project information and now also report summaries are available on CORDIS. All H2020 projects can be downloaded from the EU Open Data Portal .

My refinements


Download results of this page


Refine by:

Programme

FP7
All
FP7-NMP (8)

Language

English (8)

Advanced search

Results 1 - 8 of 8
Order by: Results/page:
1
Nanotherapeutics to Treat Antibiotic Resistant Gram-Negative Pneumonia Infections
ID: 604434
Start date: 2014-01-01, End date: 2017-12-31
The main objective of PneumoNP is the development of a theragnostic system for the treatment of lung Gram-negative bacterial infections. As a proof of concept PneumoNP will focus the attention on Klebsiella pneumoniae caused infections. A diagnostic kit will be developed to e...
Programme: FP7-NMP
Record Number: 110689
Last updated on: 2017-06-05
European Network on the Health and Environmental Impact of Nanomaterials
ID: 218539
Start date: 2008-04-01, End date: 2012-03-31
Recent technological advances allow the targeted production of objects and materials in the nanoscale (smaller than 100 nm). Nanomaterials have chemical, physical and bioactive characteristics, which are different from those of larger entities of the same materials. Nanoparti...
Programme: FP7-NMP
Record Number: 86639
Last updated on: 2017-05-30
NANOPARTICLES FOR THERAPY AND DIAGNOSIS OF ALZHEIMER DISEASE
ID: 212043
Start date: 2008-09-01, End date: 2013-08-31
The search for effective therapies and early detection strategies for Alzheimer’s Disease (AD), the major cause of dementia in Europe, is imperative. It is known that β-amyloid (Aβ) peptide plays a central role in neurodegeneration. In AD brain, Aβ is released in a soluble fo...
Programme: FP7-NMP
Record Number: 89306
Last updated on: 2017-05-29
Engineered Nanoparticles: Review of Health and Environmental Safety
ID: 218433
Start date: 2008-09-01, End date: 2009-08-31
The overall aim of the ENRHES project is to perform a comprehensive scientific review of the health and environmental safety of fullerenes, CNTs, metal and metal oxide nanomaterials. The review will consider sources, pathways of exposure, the health and environmental outcomes...
Programme: FP7-NMP
Record Number: 89325
Last updated on: 2017-05-29
Health Impact of Engineered Metal and Metal Oxide Nanoparticles: Response, Bioimaging and Distribution at Cellular and Body Level
ID: 228825
Start date: 2009-10-01, End date: 2012-09-30
Metal oxide and metal NPs are particularly dangerous for two reasons: their special catalytic activity coming from the properties of their nanointerface may interfere with numerous intracellular biochemical processes and the decomposition of NPs and the ion leakage could heav...
Programme: FP7-NMP
Record Number: 92651
Last updated on: 2017-05-25
RISK ASSESSMENT OF ENGINEERED NANOPARTICLES
ID: 228789
Start date: 2009-05-01, End date: 2012-10-31
Engineered Nanoparticles (ENP) are increasingly produced for use in a wide range of industrial and consumer products. Yet it is known that exposure to some types of particles can cause severe health effects. Therefore it is essential to ascertain whether exposure to ENP can l...
Programme: FP7-NMP
Record Number: 91280
Last updated on: 2017-05-25
THE REACTIVITY AND TOXICITY OF ENGINEERED NANOPARTICLES:  RISKS TO THE ENVIRONMENT AND HUMAN HEALTH
ID: 214478
Start date: 2008-12-01, End date: 2012-11-30
NanoReTox will identify the potential risks to the environment and human health posed by free engineered (i.e. manmade) nanomaterial by comprehensively addressing five key questions: (1) How does the environment into which nanoparticles are released affect their physicochemic...
Programme: FP7-NMP
Record Number: 89919
Last updated on: 2017-05-25
Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility
ID: 309820
Start date: 2013-02-01, End date: 2018-01-31
NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have...
Programme: FP7-NMP
Record Number: 106699
Last updated on: 2017-04-10
1
List retrieved on: 2018-08-14
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top